$8.46-0.13 (-1.51%)
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis.
LeonaBio, Inc. in the Healthcare sector is trading at $8.46 with a market capitalization of $85M. Wall Street consensus targets $18.00 (2 analysts), implying a +112.8% move over the next 12 months. The stock is currently 40% below its 52-week high of $14.21, remaining 34.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead prod...